To Compare Positron Emission Tomography (PET) Measurements of Fibrillar Amyloid Burden

Phase 2

Completed

• Conditions: Alzheimer's Disease
• Interventions: Drug: [18F]AZD4694

• Registration Number: NCT00991419
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to compare PET measurements of fibrillar amyloid burden using \[18F\]AZD4694.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-10-07
• Study First Submitted QC: 2009-10-07
• Study First Posted: 2009-10-08
• Study Start: 2010-02
• Primary Completion: 2011-08
• Study Completion: 2011-08
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-29
• Last Update Posted: 2013-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Male or female, of any race or/ethnicity
• ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician

Exclusion Criteria

• Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
• Participated in a PET study within the last 12 months
• Pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A	[18F]AZD4694	\[18F\]4694

Primary Outcome Measures

Name	Time	Method
PET Measurements	Day 1 and Day 7

Trial Locations

Locations (1)

Research Site; 🇺🇸 Phoenix, Arizona, United States